For example, monoclonal antibodies specific for CTLA-4 that prevent CTLA-4 from binding CD80/CD86 dramatically activate anti-tumor immunity, leading to improved survival of patients with advanced melanoma9. This evidence concerns the gene CTLA4 and neoplasm.